Central and Eastern European CEE Developing Markets for Pharmaceuticals 2006-2011

The purpose of visiongain’s Developing Markets Series is to examine prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe in three linked reports. Central and Eastern European (CEE) Developing Markets for Pharmaceuticals, 2006-2011 – Part 3 of Developing Markets - discusses prospects for the large developing market of Central and Eastern Europe. The other reports discuss Asia and Latin America respectively. Importantly, the growth of pharmaceutical markets in economically developing nations has the potential to offset serious problems currently being experienced by the global industry. The purpose of this visiongain report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Central and Eastern Europe, at both regional and national level.

The growth of pharmaceutical markets in the developing nations has the potential to offset serious problems currently experienced by the global industry. The principal challenge is slow growth in North America, Western Europe and Japan.

In contrast, visiongain predicts that all the leading developing markets will exhibit strong growth from 2006-2011. Rapid economic growth and large, under-served populations will drive that expansion. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors.

Central and Eastern European Developing Markets for Pharmaceuticals, 2006-2011, examines developing pharmaceutical markets critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, SWOT analyses and discussion of qualitative factors. Societal, political, economic and commercial issues are covered. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, Central and Eastern European Developing Markets for Pharmaceuticals, 2006-2011, concentrates on the following themes:

> A forecast of the global pharmaceutical market from 2006-2011, with key issues discussed

> Forecasts of sales revenues and growth rates for leading developing markets in Central and Eastern Europe from 2006-2011

> Drivers and opportunities in those markets

> Restraints and threats in those markets

> Discussion of key players and important therapeutic areas

> Discussion of relevant regulatory, societal and economic issues

> Comparison of the prospects for revenue generation in Asia, Latin America and Central/Eastern Europe, with overall forecasts for those regions

> Why you should buy this report:

To receive a comprehensive analysis of the prospects for developing regional and national markets for pharmaceuticals in Central and Eastern Europe from 2006-2011, as well as comparative data for other developing regions

To discover predicted revenues, growth rates and other key metrics for Central and Eastern European developing markets from 2006-2011

To determine the forces that influence pharmaceutical sales in the Central and Eastern European developing markets:

- Competitive characteristics of the market, both at national and regional level

- Regulatory, technological, societal and political issues

- Drivers and restraints

- Strengths, weaknesses, opportunities and threats

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for approximately 85% of revenues for prescription drugs. However, there is concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are very interested in raising their profiles in the developing markets of Asia, Latin America and Eastern/Central Europe.

Growth of the pharmaceutical markets in developing nations will clearly surpass that of the established markets. That situation will provide one of the greatest opportunities currently available to the international pharmaceutical industry. Many developing countries have strongly growing economies; that factor constitutes a driving force in the reform and broadening of healthcare systems. Improvements in both the quality and reach of these healthcare provisions will drive the sales of branded and generic products. Private healthcare will undergo similar developments.

Manufacturers of pharmaceuticals are currently working hard to address unmet healthcare needs in developing countries. By doing so, they are making better treatments available to millions of patients and improving the overall performance of their companies.

Organizations listed:

Abbott Laboratories

Abdi Ibrahim

Ablomed

Actavis

Adamed

Akrikhin

Alkem

Alpharma

Apex International Clinical Research

Armstrong

AstraZeneca

Bagó

Barr Pharmaceuticals

Bayer

Berlin-Chemie

Bristol-Myers Squibb

Bryntsalov A

Cadila Healthcare

Choong Wae

Cipla

Dae Woong

Dexa Medica

Dong A

Dr Reddy’s Laboratories

Eczacibasi

Egis

Elea

Eli Lilly

F. Hoffman-La Roche

Fresenius

Gador

Gedeon Richter

Genovate Biotec

Geven

GlaxoSmithKline

Guangzhou Tainxin

Han Mi

Heilongjiang Haerbin Pharmaceutical

Hexal

Hoechst Marion Roussel

ICON

II Dong

Immunopreparat

Interbat

Ivax Pharmaceuticals

Jiangsu Lianyungang Hengrui

Johnson & Johnson

Kalbe Farma

Krka

KRKA D.D.

Lek

Menarini

Merck & Co

Merck KGaA

Merck Sharp Dohme

Moskhimpharmpreparaty

MSD Korea

Mylan Laboratories

Nicholas Piramal

Nizpharm

Novartis

Novo Nordisk

Nycomed

Omnicare CR

Otechestvennye Lekarstiva

Otsuka Pharmaceutical

Pascual Laboratories

Perlican

Pfizer

PHARM-CENTR

Pharmstandart

Phoenix

Pliva

Polfa Kutno

Polfa Warszawa

Polpharma SA

Protech Pharmaservice

Quintiles

Ranbaxy Laboratories

Roche

Roemmers

Sanbe Farma

Sandoz

Sanofi-Aventis

Schering Plough

Schwarz Pharmaceutical

Servier Pharmaceuticals

Siam Pharma

Soul-Pattinson

Sun Pharmaceutical Industries

Teva Pharmaceutical

Trans-India Acquisition Corporation

Unichem

United Laboratories

Veropharm

Virginia CRO

VIRION

Watson Pharmaceuticals

Wockhardt

Wyeth

Yangzijiang Pharmaceutical

Yuhan Company

Yung Shin Pharmaceutical Industries

Zentiva

Zydus Cadila

Lead Analyst: Dr Gordon Low Publication Date: 23/11/06 Pages: 97

Single user licence: The Report is delivered via an on-line reading room. One use access only, the report is in Flash format in a printable format.

Department: Report is delivered via an on line reading room. Five user access only, the report is in Flash format in a printable format.

Company/site wide licence: The report is delivered in email format as a PDF document with no locking system attached. The report can be loaded onto the company's intranet site.

Table of Contents

Price
Single User Licence $3998.00
Company-wide Intranet Licence $11,998.00
Department Licence 5 Users $7998.00